MyCheck Cancer

MyCheck Cancer assesses tumor-associated mutations that are being passed along from generation to generation.

Cancer is the world’s second deadliest disease, so it’s unfortunate but no surprise that many families have at least a few members who have had cancer. Sometimes, certain types of cancer seem to run in some families. Although this is often referred to as inherited cancer, what is inherited is the abnormal gene that can lead to cancer, not the cancer itself.

People that inherit these abnormal genes are more susceptible to cancer development. Identifying those at high risk enables implementation of additional screening, surveillance, and interventions.

People can inherit germline (egg and sperm) mutations in their parents and, with them, the pre-disposition to develop the tumor associated with that alteration.

MyCheck Cancer must be considered by people if there is:

• a clinical history indicative of a hereditary cancer syndrome
• a family history presenting with multiple cancer types
• cancer diagnosed at an unusually young age in the family
• cancer that has developed in both organs of a set of paired organs (e.g., both kid-neys, both
• breasts)
• several close blood relatives that have the same type of cancer
• unusual cases of a specific cancer type (e.g., male breast cancer)

MyCheck Cancer is a susceptibility test, that is, it evaluates the predisposition to develop a male hereditary tumor.

The genes analyzed (90 in men, 85 in women) are associated with hereditary forms of the following cancers:

• brain
• thyroid
• liver
• stomach
• kidney
• eyes
• otherwise
• pancreas
• intestine
• bladder
• male and female reproductive system

People with a pathogenic variant in one of these genes have an increased risk of developing certain cancers, many of which may be difficult both to detect and to treat.

MyCheck Cancer leverages Next Generation Sequencing (NGS) technology to examine regions of the human genome that tend to get missed by other methods of single or hotspot bi-omarker testing.

The advantages of this test are:

• It results in risk-reduction and early diagnosis, increasing the chances of successful treatment and survival.
• The early identification of mutations allows the launch of an oncological prevention pro-gram based on the monitoring of genetic stability and on lifestyle interventions.
• It determines the genetic causes of hereditary cancers in one’s own family.

MyCheck Cancer is performed using NGS on the DNA extracted from a peripheral blood sample.

1. The blood sample is sent to Bioscience laboratories for genetic testing.
2. DNA is isolated.
3. The DNA library is then prepared and sequenced on a NGS sequencer.
4. Seamless integration of our informatics solutions with our sequencing platforms enables quick and intuitive analysis and reporting once the sequencing is completed

To request MyCheck Cancer, or for more information about the test, please feel free to call us at +971 (0)4 375 722 or fill in this form:

(*) field required